The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System

Inclusion Criteria: * Age ≥18 years, and \<80 years with a definite diagnosis of asthma for at least 6 months * Patients met the 2024 GINA criteria for severe asthma, which was defined as "uncontrolled" asthma (frequent asthma symptoms, or frequent acute exacerbations) despite high-dose inhaled corticosteroids (ICS) plus long-acting β2-receptor antagonists (LABAs), or worsening of symptoms after slight tapering of high-dose therapy. * They were willing to accept multi-disciplinary and multi-dimensional evaluation and signed informed consent * Informed consent was obtained and patients were able to participate in the study and 6-month follow-up according to the protocol Exclusion Criteria: * The presence of numerous other lung tissue destructive diseases, such as severe bronchiectasis or pulmonary tuberculosis. * Chest surgery or abdominal surgery in the past 3 months * Eye surgery had been performed within the past 3 months * Myocardial infarction within the previous 3 months * Anti-tuberculosis treatment is ongoing * Women who are pregnant and lactating * Macrolide use within 4 weeks before the screening period * Treatment with anti-ige, anti-IL-5, or anti-IL-5R within 4 weeks before the screening period * Inhaled ICS+LABA+ long-acting anticholinergic agent (LAMA) for 4 weeks prior to the screening period 4. Allergy to macrolides * QTc interval prolongation \>480ms * Taking medications that interact with azithromycin, causing QTc prolongation or existing ECG abnormalities, may lead to arrhythmia